FLT3 inhibitors for relapsed or refractory acute myeloid leukaemia
Mené aux Etats-Unis, en Europe et au Canada sur 333 patients atteints d'une leucémie myéloïde aiguë réfractaire ou récidivante, cet essai de phase II évalue l'efficacité, du point de vue de la proportion de patients obtenant une rémission complète composite et une rémission complète, et la toxicité du quizartinib, un inhibiteur de tyrosine kinase anti-FLT3, utilisé en monothérapie
FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations occur in approximately 30% of patients with acute myeloid leukaemia.1 Patients with FLT3-ITD-mutated acute myeloid leukaemia, particularly those with a high allelic frequency, relapse quickly and have a shortened overall survival compared with patients who have the wild-type FLT3. In 2017, the FLT3 and multikinase inhibitor midostaurin was approved by the US Food and Drug Administration in combination with induction chemotherapy, for the treatment of patients with newly diagnosed acute myeloid leukaemia with a FLT3-ITD or tyrosine kinase domain (TKD) mutation, based on a 7% improvement in 5-year overall survival in a randomised phase 3 trial.
The Lancet Oncology , commentaire, 2017